Alpha-synuclein transgenic models

Test potential therapeutics for Parkinson’s disease and other synucleinopathies in mouse models with alpha-synuclein deposition and downstream pathological events

Home » Neurology Research Models and Services  » Parkinson’s models and services » Parkinson’s models – Transgenic alpha-synuclein models
Parkinson’s disease (PD) is a neurodegenerative disorder that affects the motor systems in early stages, leading to symptoms such as trembling, slowing of movement, and muscle stiffness. The distinct disease mechanism can be modelled in different mouse models of PD. 

Alpha-synuclein (α-syn) inclusions are the main histopathological hallmark correlating with clinical symptoms of not only PD, but also other synucleinopathies such as dementia with Lewy bodies (DLB), and multiple systems atrophy (MSA).

InnoSer offers fee-for-service transgenic α-syn mouse models. Transgenic α-syn mouse models faithfully recapitulate α-syn pathophysiology found in PD, DLB and MSA. As various models of α-syn pathology are available; the choice of the model depends on your compound’s mechanism of action and your research goals.  

Take advantage of InnoSer’s behavioural research expertise, flexibility, and collaborative approach for your research. Our in-house neurology experts have long-standing experience modelling PD in vivo using transgenic mouse lines and other neurodegenerative diseases. Our neurology experts help guide your decision on choosing the best model fit for your current research goals. 

Transgenic alpha-synuclein models that InnoSer offers:

  • Human α-syn models.
  • A53T α-syn models (e.g. M83).
  • Seeding in α-syn transgenic models.

Find the right model for you.

Compare our model capabilities and discover which of our neurology platforms suits your research needs

Belgian based preclinical neurology CRO mouse models

Key readouts

Test the efficacy of your treatments in the following battery of behavioural tests:

Test the efficacy of your treatments with the following biological readouts:

Related Parkinson’s Disease model options

MPTP Induced PD Models

InnoSer offers unique services using MPTP-based inducible PD models.

Seeding Alpha-Synuclein Models

InnoSer has extensive experience with α-syn seeding using both PD patient-derived brain extracts and recombinant seeds.


InnoSer has extensive experience with the administration of neurotoxic compounds such as 6-OHDA to induce PD phenotypes in vivo.

AAALAC Accreditation

InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.


Animal Welfare

The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.

Need more information?

If you have any questions about how we can help accelerate your research,

then let us know